Literature DB >> 21352129

Insight in first episode psychosis: who is measuring what?

Constantin Tranulis1, Martin Lepage, Ashok Malla.   

Abstract

AIMS: To compare different self-administered or clinician-rated insight scales in an FEP population.
METHODS: A self-administered measure (Beck Cognitive Insight Scale - BCIS) and clinician-rated scales (Scale of Unawareness of Mental Disorder - SUMD and Positive And Negative Symptoms Scale - PANSS-G12 insight item) were completed by 38 patients with a diagnosis of FEP.
RESULTS: The scales had good internal consistency and only the clinician-rated scales were intercorrelated (SUMD - awareness of mental disorder and PANSS-G12 items (r=0.657, P<0.001)). Moreover, we observed a significant association of SUMD and PANSS positive and general subscales and a trend association for BCIS and PANSS negative subscale.
CONCLUSION: Differential associations observed between insight and symptoms may suggest different clinical predictive values for each measure. Our results suggest the necessity to qualify the term 'insight' when discussing research results, most notably with respect to who is rating and what aspect of insight is being rated.
© 2008 The Authors.

Entities:  

Mesh:

Year:  2008        PMID: 21352129     DOI: 10.1111/j.1751-7893.2007.00054.x

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  14 in total

Review 1.  Assessment of cognitive insight: a qualitative review.

Authors:  Sally E Riggs; Paul M Grant; Dimitri Perivoliotis; Aaron T Beck
Journal:  Schizophr Bull       Date:  2010-08-06       Impact factor: 9.306

2.  Clinical and Cognitive Insight in a Compensatory Cognitive Training Intervention.

Authors:  Cynthia Z Burton; Lea Vella; Elizabeth W Twamley
Journal:  Am J Psychiatr Rehabil       Date:  2011-10-01

3.  Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness.

Authors:  Piotr J Quee; Lisette van der Meer; Richard Bruggeman; Lieuwe de Haan; Lydia Krabbendam; Wiepke Cahn; Niels C L Mulder; Durk Wiersma; André Aleman
Journal:  Schizophr Bull       Date:  2010-11-22       Impact factor: 9.306

4.  Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.

Authors:  J-G Daneault; A Maraj; M Lepage; A Malla; N Schmitz; S N Iyer; R Joober; J L Shah
Journal:  Acta Psychiatr Scand       Date:  2019-04       Impact factor: 6.392

5.  Metacognition as a Mediating Variable Between Neurocognition and Functional Outcome in First Episode Psychosis.

Authors:  Geoff Davies; David Fowler; Kathryn Greenwood
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

6.  Cognitive insight and objective quality of life in people with schizophrenia and auditory hallucinations.

Authors:  Ruchika Rathee; Tanya M Luhrmann; Triptish Bhatia; Smita N Deshpande
Journal:  Psychiatry Res       Date:  2017-09-13       Impact factor: 3.222

7.  Failures of metacognition and lack of insight in neuropsychiatric disorders.

Authors:  Anthony S David; Nicholas Bedford; Ben Wiffen; James Gilleen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-05-19       Impact factor: 6.237

Review 8.  Systematic review reveals heterogeneity in the use of the Scale to Assess Unawareness of Mental Disorder (SUMD).

Authors:  Rémy Dumas; Karine Baumstarck; Pierre Michel; Christophe Lançon; Pascal Auquier; Laurent Boyer
Journal:  Curr Psychiatry Rep       Date:  2013-06       Impact factor: 5.285

9.  Assessing cognitive insight in nonpsychiatric individuals and outpatients with schizophrenia in Taiwan: an investigation using the Beck Cognitive Insight Scale.

Authors:  Yu-Chen Kao; Tzong-Shi Wang; Chien-Wen Lu; Yia-Ping Liu
Journal:  BMC Psychiatry       Date:  2011-10-21       Impact factor: 3.630

10.  Relationship between cognitive insight and subjective quality of life in outpatients with schizophrenia.

Authors:  Jong-Hoon Kim; Seul Lee; Ah-Young Han; Kyungwook Kim; Jinyoung Lee
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-07       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.